WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 100640
CAS#: 53-19-0
Description: Mitotane is a synthetic derivative of the insecticide dichlorodiphenyl trichloroethane (DDT) with anti-adrenocorticoid properties. Following its metabolism in the adrenal cortex to a reactive acyl chloride intermediate, mitotane covalently binds to adrenal proteins, specifically inhibiting adrenal cortical hormone production.
MedKoo Cat#: 100640
Name: Mitotane
CAS#: 53-19-0
Chemical Formula: C14H10Cl4
Exact Mass: 317.95366
Molecular Weight: 320.04
Elemental Analysis: C, 52.54; H, 3.15; Cl, 44.31
Synonym: CB313; CB-313; CB 313; WR13045; WR-13045; WR 13045; DDD, Chloditan; Chlodithane; Khloditan; Mytotan; brand name: Lysodren. Lisodren.
IUPAC/Chemical Name: 1-chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene
InChi Key: JWBOIMRXGHLCPP-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
SMILES Code: ClC1=CC=C(C(C2=CC=CC=C2Cl)C(Cl)Cl)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 320.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Terzolo M, Zaggia B, Allasino B, De Francia S. Practical treatment using mitotane for adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2014 Jun;21(3):159-65. doi: 10.1097/MED.0000000000000056. Review. PubMed PMID: 24732405.
2: Tripto-Shkolnik L, Blumenfeld Z, Bronshtein M, Salmon A, Jaffe A. Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. J Clin Endocrinol Metab. 2013 Feb;98(2):443-7. doi: 10.1210/jc.2012-2839. Epub 2012 Dec 28. Review. PubMed PMID: 23275528.
3: Menaa F, Menaa B. Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adreno-cortical carcinoma. Curr Med Chem. 2012;19(34):5854-62. Review. PubMed PMID: 22934807.
4: Terzolo M, Ardito A, Zaggia B, Laino F, Germano A, De Francia S, Daffara F, Berruti A. Management of adjuvant mitotane therapy following resection of adrenal cancer. Endocrine. 2012 Dec;42(3):521-5. doi: 10.1007/s12020-012-9719-7. Epub 2012 Jun 17. Review. PubMed PMID: 22706605.
5: De Francia S, Ardito A, Daffara F, Zaggia B, Germano A, Berruti A, Di Carlo F. Mitotane treatment for adrenocortical carcinoma: an overview. Minerva Endocrinol. 2012 Mar;37(1):9-23. Review. PubMed PMID: 22382612.
6: Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2011 Nov;75(5):585-91. doi: 10.1111/j.1365-2265.2011.04214.x. Review. PubMed PMID: 21883349.
7: Sane T. [Mitotane in the treatment of adrenal carcinoma]. Duodecim. 2010;126(17):2040-6. Review. Finnish. PubMed PMID: 21053521.
8: Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009 Sep 20;27(27):4619-29. doi: 10.1200/JCO.2008.17.2775. Epub 2009 Aug 10. Review. PubMed PMID: 19667279; PubMed Central PMCID: PMC2754909.
9: Reine NJ. Medical management of pituitary-dependent hyperadrenocorticism: mitotane versus trilostane. Clin Tech Small Anim Pract. 2007 Feb;22(1):18-25. Review. PubMed PMID: 17542193.
10: Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005 Apr;6(4):386-94. Review. PubMed PMID: 15898346.
11: Peterson ME, Kintzer PP. Medical treatment of pituitary-dependent hyperadrenocorticism. Mitotane. Vet Clin North Am Small Anim Pract. 1997 Mar;27(2):255-72. Review. PubMed PMID: 9076906.
12: Parma A, D'Agnolo B. [Adrenocortical carcinoma and its treatment with mitotane. Description of a case]. Minerva Med. 1991 Dec;82(12):883-8. Review. Italian. PubMed PMID: 1780099.
13: Touitou Y, Bogdan A, Legrand JC, Desgrez P. [Metabolism of o,p'-DDD (mitotane) in human and animals. Actual notions and practical deductions (author's transl)]. Ann Endocrinol (Paris). 1977;38(1):13-25. Review. French. PubMed PMID: 324349.
